Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies

ID: NCT03367819
Status: Recruiting
Phase: Phase 1/Phase 2
Start Date: January 04, 2018
First Submitted: December 05, 2017
Last Updated: February 14, 2018
Results: N/A
Organization: Sanofi
Sponsors & Collaborators: Sanofi
Location: Taiwan
Conditions: Prostate Cancer, Non-small Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Study Description

Brief Summary

Primary Objectives:

- To characterize the safety and tolerability of isatuximab in combination with REGN2810 in patients with metastatic, castration-resistant prostate cancer (mCRPC) who are naïve to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PDL-1)-containing therapy, or non-small cell lung cancer (NSCLC) who progressed on anti-PD-1/PDL-1-containing therapy, and to confirm the recommended Phase 2 dose (RP2D).

- To assess the response rate of isatuximab in combination with REGN2810 in patients with either mCRPC who are anti-PD-1/PDL-1 therapy naive, or NSCLC who progressed on anti-PD-1/PDL-1 therapy, or of isatuximab as single agent in patients with mCRPC.

Secondary Objectives:

- To evaluate the safety of the combination of isatuximab with REGN2810 or isatuximab monotherapy.

- To evaluate the immunogenicity of isatuximab and REGN2810.

- To characterize the pharmacokinetic (PK) profile of isatuximab single agent or in combination with REGN2810, and to characterize the PK of REGN2810 in combination with isatuximab.

- To assess overall efficacy of isatuximab in combination with REGN2810 or as a single agent.

Detailed Description

The total study duration per patient is up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.
Condition or disease Intervention/treatment Phase

Non-small Cell Lung Cancer

Prostate Cancer

Drug: Isatuximab SAR650984
Other Names
Drug: REGN2810
Other Names
Phase 1/Phase 2

Tracking Information

First Submitted DateDecember 05, 2017
Last Update Posted DateFebruary 14, 2018
Actual Start DateJanuary 04, 2018
Anticipated Completion DateJuly 30, 2021
Actual Primary Completion DateJuly 30, 2021
Results First Submitted DateN/A
Received Results Disposit DateN/A

Current Primary Outcome Measures

  • Response Rate [Time Frame: Up to 6 months from last patient in]

    In non-small cell lung cancer (NSCLC): assessed and objective responses by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; In metastatic castration-resistant prostate cancer (mCRPC): response will be defined per Prostate Cancer Working Group 3 (PCWG3) criteria

  • AEs [Time Frame: Up to 30 days after last study treatment administration (Up to approximately 25 months after first study treatment administration)]

    Number of patients with AEs based on standard and systematic assessment including changes in laboratory tests and vital signs, according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 Grade scaling

  • Dose Limiting Toxicities (DLTs) [Time Frame: Up to 3 weeks after first study treatment administration]

    DLTs are following adverse events (AEs) in Cycle 1 unless due to disease progression or an obviously unrelated cause: Grade (G) 4 neutropenia >7 days; G 3 to 4 neutropenia with fever or documented infection; G 3 to 4 thrombocytopenia with bleeding requiring intervention; G 4 non-hematological AE; G ≥2 uveitis; G 3 non-hematological AE >3 days despite supportive care (with defined exceptions); Delay in initiation of the 2nd cycle >14 days for related laboratory abnormalities/AEs

Original Primary Outcome Measures

Not Available

Current Secondary Outcome Measures

  • Immunogenicity: isatuximab [Time Frame: Up to 90 days following the last administration of study treatment or until the sample is negative (Up to approximately 27 months after first study treatment administration)]

    Levels of anti-drug antibody against isatuximab

  • Pharmacokinetic (PK) parameters: area under the curve (AUC) [Time Frame: Up to 3 weeks after first study treatment administration]

    AUC is area under the drug concentration versus time curve

  • Tumor burden change [Time Frame: Up to 6 months from last patient in]

    The best percent-change from baseline in a sum of the diameters for all target lesions

  • Duration of response [Time Frame: Up to 6 months from last patient in]

    Defined as the time from the date of the first response that is subsequently confirmed to the date of first confirmed disease progression or death, whichever occurs first

  • Progress-free survival [Time Frame: Up to 6 months from last patient in]

    Defined as time from the first study treatment administration to the date of first documentation of progressive disease that is subsequently confirmed or the date of death from any cause

  • Assessment of PK parameter: Cmax [Time Frame: Up to 3 weeks after first study treatment administration]

    Cmax is maximum drug concentration observed

  • Immunogenicity: REGN2810 [Time Frame: Up to 90 days following the last administration of study treatment or until the sample is negative (Up to approximately 27 months after first study treatment administration)]

    Levels of anti-drug antibody against REGN2810

Original Secondary Outcome Measures

Not Available

Study Design

Brief TitleIsatuximab in Combination With REGN2810 in Patients With Advanced Malignancies
Official TitleA Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With REGN2810, or Isatuximab Alone, in Patients With Advanced Malignancies
Brief Summary

Primary Objectives:

- To characterize the safety and tolerability of isatuximab in combination with REGN2810 in patients with metastatic, castration-resistant prostate cancer (mCRPC) who are naïve to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PDL-1)-containing therapy, or non-small cell lung cancer (NSCLC) who progressed on anti-PD-1/PDL-1-containing therapy, and to confirm the recommended Phase 2 dose (RP2D).

- To assess the response rate of isatuximab in combination with REGN2810 in patients with either mCRPC who are anti-PD-1/PDL-1 therapy naive, or NSCLC who progressed on anti-PD-1/PDL-1 therapy, or of isatuximab as single agent in patients with mCRPC.

Secondary Objectives:

- To evaluate the safety of the combination of isatuximab with REGN2810 or isatuximab monotherapy.

- To evaluate the immunogenicity of isatuximab and REGN2810.

- To characterize the pharmacokinetic (PK) profile of isatuximab single agent or in combination with REGN2810, and to characterize the PK of REGN2810 in combination with isatuximab.

- To assess overall efficacy of isatuximab in combination with REGN2810 or as a single agent.

Detailed Description

The total study duration per patient is up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.

Study TypeInterventional
Study PhasePhase 1/Phase 2
Estimated Enrollment
134
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
None (Open Label)
Primary Purpose
Treatment
Conditions
Non-small Cell Lung Cancer
Prostate Cancer
Target Follow-Up Duration N/A
Biospecimen:
N/A
Sampling MethodN/A
Study PopulationN/A
Intervention
Drug: Isatuximab SAR650984

Pharmaceutical form: solution for infusion Route of administration: intravenous

Other Names
Drug: REGN2810

Pharmaceutical form: solution for infusion Route of administration: intravenous

Other Names
Study Groups/Cohorts
Phase 1: mCRPC/NSCLC
Isatuximab dose 1 and REGN2810 predefined dose

Cohort A-1: mCRPC, isatuximab and REGN2810 combination
Patients with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose

Cohort A-2: mCRPC, isatuximab monotherapy
Patients with mCRPC will be given isatuximab dose 2

Phase 2 Cohort B: NSCLC
Patients with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose

Phase 2 Cohort C: mCRPC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in patients with mCRPC

Phase 2 Cohort D: NSCLC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose

Study Arms
Experimental Cohort A-1: mCRPC, isatuximab and REGN2810 combination
Patients with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Cohort A-1: mCRPC, isatuximab and REGN2810 combination
Patients with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : REGN2810
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Cohort A-2: mCRPC, isatuximab monotherapy
Patients with mCRPC will be given isatuximab dose 2
Drug : Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 1: mCRPC/NSCLC
Isatuximab dose 1 and REGN2810 predefined dose
Drug : Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 1: mCRPC/NSCLC
Isatuximab dose 1 and REGN2810 predefined dose
Drug : REGN2810
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 2 Cohort B: NSCLC
Patients with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 2 Cohort B: NSCLC
Patients with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : REGN2810
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 2 Cohort C: mCRPC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in patients with mCRPC
Drug : REGN2810
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 2 Cohort C: mCRPC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in patients with mCRPC
Drug : Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 2 Cohort D: NSCLC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
Drug : Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous

Experimental Phase 2 Cohort D: NSCLC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
Drug : REGN2810
Pharmaceutical form: solution for infusion Route of administration: intravenous

Arm Intervention/Treatment
Experimental Cohort A-1: mCRPC, isatuximab and REGN2810 combination
Patients with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : Isatuximab SAR650984
Experimental Cohort A-1: mCRPC, isatuximab and REGN2810 combination
Patients with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : REGN2810
Experimental Cohort A-2: mCRPC, isatuximab monotherapy
Patients with mCRPC will be given isatuximab dose 2
Drug : Isatuximab SAR650984
Experimental Phase 1: mCRPC/NSCLC
Isatuximab dose 1 and REGN2810 predefined dose
Drug : Isatuximab SAR650984
Experimental Phase 1: mCRPC/NSCLC
Isatuximab dose 1 and REGN2810 predefined dose
Drug : REGN2810
Experimental Phase 2 Cohort B: NSCLC
Patients with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : Isatuximab SAR650984
Experimental Phase 2 Cohort B: NSCLC
Patients with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug : REGN2810
Experimental Phase 2 Cohort C: mCRPC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in patients with mCRPC
Drug : REGN2810
Experimental Phase 2 Cohort C: mCRPC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in patients with mCRPC
Drug : Isatuximab SAR650984
Experimental Phase 2 Cohort D: NSCLC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
Drug : Isatuximab SAR650984
Experimental Phase 2 Cohort D: NSCLC
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
Drug : REGN2810

Recruitment Information

Recruitment Status:Recruiting
Enrollment134
Completion DateJuly 30, 2021
Eligibility Criteria: Inclusion criteria:
- Patients must have a known diagnosis of either metastatic castration-resistant prostate cancer (mCRPC) or non-small cell lung cancer (NSCLC) with evidence of measurable disease.
- Failure of, inability to, or refusal to receive standard of care.
- ≥18 years of age.
Exclusion criteria:
- Prior exposure to isatuximab or participation in clinical studies with isatuximab.
- For patients with mCRPC, prior exposure to any agent (approved or investigational) that blocks the PD-1/PD-L1 pathway.
- Evidence of other immune related disease /conditions.
- History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.
- Has received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
- Prior solid organ or hematologic transplant.
- Eastern Cooperative Oncology Group performance status (PS) ≥2.
- Poor bone marrow reserve.
- Poor organ function.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
GenderAll
Age18 Years to N/A
Accepts Healthy VolunteersNo
Contacts
Listed Location Countries
Taiwan

Administrative Information

NCT Number:NCT03367819
Other Study ID Numbers
ACT15319
2017-002846-61
U1111-1197-7792
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Device Product Not Approved or Cleared by U.S. FDA: No
IPD Sharing Statement
Not Available
Responsible Party,
Study Sponsor
Sanofi
Collaborators
Not Available
Investigators
Study Director
Clinical Sciences & Operations
Sanofi